INDP Indaptus Corp: רווח נקי למניה ב-12 החודשים האחרונים

Indaptus Therapeutics (INDP) maintains pricing power in oncology through a unique method of immune activation via bacteria. This YoY TTM earnings per share chart illustrates profitability trends, where 81.70 captures the current value of the indicator. A flawless reputation within the scientific community complements an asset-light R&D model that relies on external contractors for drug synthesis.

Indaptus Therapeutics (INDP) maintains an impeccable reputation in the field of onco-immunology due to its innovative approach to therapy. The daily calculation of the annual change in net earnings per share over a rolling period allows for the rapid tracking of market consensus while eliminating quarterly distortions. This metric measures yield dynamics, revealing the actual efficiency of capital management. Analyzing this chart helps determine the true resilience of the business, which is critical for assessing the fair value of the shares.